Dow Jones Industrial Average Pulls Back On Cyber Monday

The Drug Stock Up Almost 20%

Nov 28, 2016 at 12:18 PM

The Dow Jones Industrial Average (DJIA) is trading lower, as stocks take a breather after last week's impressive run to all-time highs. Today's pullback -- which isn't necessarily unexpected -- comes even as January-dated crude futures trade up 2.7% at $47.30 per barrel, as major oil players give mixed signals over a potential production cut ahead of Wednesday's Organization of Petroleum Exporting Countries (OPEC) meeting. Meanwhile, absent any significant economic reports, retail stocks are in focus on Cyber Monday, although shares of Amazon.com, Inc. (NASDAQ:AMZN) were last seen trading almost 2% lower.

Continue reading for more on today's market -- and don't miss:

What has this drug stock surging almost 20%.
How this IT stock can surge 69% in the next year, courtesy of Elliott Management.
Checking in on the CBOE Volatility Index (VIX), the SPDR S&P 500 ETF Trust (SPY), and other noteworthy stats at midday.
Plus... the drugmaker downed by a bearish brokerage note, the biotech that's nearly doubled, and one of the Nasdaq's biggest losers.

MMC 161128

Among the stocks with unusual volume at midday is biotech AstraZeneca plc (ADR) (NYSE:AZN), after a price-target cut from J.P. Morgan Securities. AZN is currently trading down 1.4% at $26.71, with call options crossing at 11 times their average intraday rate -- outpacing puts 22,000 to 1,600.

Biotech PhaseRx Inc (NASDAQ:PZRX) is among the top performers on the Nasdaq, with the shares currently trading 92.9% higher at $2.18. Earlier, the company announced its liver disease treatment, PRX-OTC, has been given an orphan drug designation by the U.S. Food and Drug Administration (FDA). PZRX is a Wall Street rookie, and is on pace to close above its 50-day moving average for the first time ever.

PZRX 161128

Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP) is among the worst performers on the Nasdaq, currently trading down 9.4% at $30.71. Weighing on the stock is the biotech's mixed earnings report and the FDA's delayed approval for AAAP's Lutathera treatment for neuroendocrine tumors. AAAP is on the short-sale restricted (SSR) list, and is now down 1.8% in 2016.

The CBOE Volatility Index (VIX) is 5.8%, or 0.7 point, at $13.05.

Today's put/call volume ratio on the SPDR S&P 500 ETF Trust (SPY) is at 1.67, with puts leading calls. At last check, SPY was down 0.5 point, or 0.2% at $221.07.

Find out where the Dow lands right after the closing bell. Sign up now for Schaeffer's Market Recap

Follow @Schaeffers

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!